HD-OPM Archive
Topics › Lp(a)

Lilly's experimental drug cut Lp(a) by 94% in a mid-stage trial; outcome data pending

Gokhan Can · Mar 30, 2025 · ♥ 22 reactions · 13 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

A Reuters report that the highest dose of an experimental Lilly drug lowered Lp(a), a genetic risk factor, by 94% in a mid-stage trial. Gokhan notes the key question is whether these drugs reduce cardiovascular events.

We should soon see how well these drugs work not only for lowering lp(a) but also cardiovascular events.

reuters.comExperimental lilly drug cuts genetic heart disease risk factor by trialThe highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.reuters.com

Research cited

#cardiovascular
← newer: Anecdote: untreated type 2 diabetes managed with carnivore dolder: Another low-carb figure addresses high ApoB, Lp(a) and plaqu →